Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma

Histopathology

Volumn 56, Issue 2, 2010, Pages 180-187

  Leroy, Xavier ^a   Aubert, Sebastien ^a   Zini, Laurent ^a   Franquet, Helene ^a   Kervoaze, Gwenola ^b   Villers, Arnauld ^a   Delehedde, Maryse ^b   Copin, Marie Christine ^a   Lassalle, Philippe ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Clear cell renal cell carcinoma; Endocan; Kidney; Papillary carcinoma; VEGF

Indexed keywords

CD34 ANTIBODY; ENDOCAN; ENDOTHELIAL CELL SPECIFIC MOLECULE 1; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; PROTEOGLYCAN; SUNITINIB; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CELL CULTURE; CELL VIABILITY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCAN GENE; ENZYME IMMUNOASSAY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; PAPILLARY CARCINOMA; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; PROTEOGLYCANS; PYRROLES; UMBILICAL CORD; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73449131546     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03458.x     Document Type: Article

References (33)

1. Cohen HT, McGovern FJ. Renal cell carcinoma. N. Engl. J. Med. 2005 353 2477 2490.
2. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007 12 1404 1415.
3. Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat. Rev. 2005 31 536 545.
4. Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007 67 1257 1264.
5. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006 24 16 24.
6. Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol. 2008 5 378 391.
7. Lassalle P, Molet S, Janin A et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J. Biol. Chem. 1996 271 20458 20464.
8. Béchard D, Gentina T, Delehedde M et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J. Biol. Chem. 2001 276 4 8341.
9. Van't veer LJ, Dai H, Van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 415 530 536.
10. Borczuk AC, Shah L, Pearson GD et al. Molecular signatures in biopsy specimens of lung cancer. Am. J. Respir. Crit. Care Med. 2004 170 167 174.
11. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene 2003 22 3070.
12. Grigoriu BD, Depontieu F, Scherpereel A et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin. Cancer Res. 2006 12 4575 4582.
13. Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig. Dis. Sci. 2009 54 389 394.
14. Mertz KD, Demichelis F, Kim R et al. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear renal cell cancer. Hum. Pathol. 2007 38 1454 1462.
15. Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumor cell proliferation, microvessel density and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 2002 196 186 193.
16. Amatschek S, Koenig U, Auer H et al. Tissue-wide expression profiling using c-DNA subtraction and microarrays to identify tumor-specific genes. Cancer Res. 2004 64 844 856.
17. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, Hughes CC. Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc. Res. 2002 63 159 171.
18. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003 27 31.
19. Eble JN ed. Tumours of the urinary system and male genital organs. Lyon : WHO, IARC, 2004.
20. Adam E, Sarrazin S, Landolfi C et al. Efficient long-term and high-yielded production of a recombinant proteoglycan in eukaryotic HEK293 cells using a membrane-based bioreactor. Biochem. Biophys. Res. Commun. 2008 369 297 302.
21. Lassalle P, Lagrou C, Delneste Y et al. Human endothelial cells transfected by SV40 T antigens: characterization and potential use as a source of normal endothelial factors. Eur. J. Immunol. 1992 22 425 431.
22. Sarrazin S, Adam E, Lyon M et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta 2006 1765 25 37.
23. Scherpereel A, Gentina T, Grigoriu B et al. Overexpression of endocan induces tumor formation. Cancer Res. 2003 63 6084 6089.
24. Scherpereel A, Depontieu F, Grigoriu B et al. Endocan, a new endothelial marker in human sepsis. Crit. Care Med. 2006 34 532 537.
25. Rennel E, Mellberg S, Dimberg A et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp. Cell Res. 2007 313 1285 1294.
26. Kaelin WG. The Von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 2007 13 680 684.
27. Ljunberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K, Rasmuson T. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int. 2006 98 661 667.
28. Furge KA, Chen J, Koeman J et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high grade papillary renal cell carcinoma. Cancer Res. 2007 67 3171 3176.
29. Lim DL, Ko R, Paulter SE. Current understanding of the molecular mechanisms of kidney cancer: a primer for urologist. Can. Urol. Assoc. J. 2007 2 (Suppl. S13 S20.
30. Rini B, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab - refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008 26 3743 3748.
31. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin. Cancer Res. 2007 13 1098 1106.
32. Norden-Zfoni A, Desai J, Manola J et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 2007 13 2643 2650.
33. Almog N, Ma L, Raychowdhury R, et al. Transcriptional switch of dormant tumors to fast growing angiogenic phenotype. Cancer Res. 2009 69 836 844.